BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2025 and business updates for the fourth quarter ended December 31,

The Buck Institute for Research on Aging today announced the launch of Healthspan Horizons, a new initiative designed to address one of the most urgent challenges in modern medicine: how to measure, understand, and extend healthspan—the years of life spent in good health. People are living longer—but

For the first time, the Neuroscience of Vitality and Aging (NOVA) Conference is bringing together leaders from across neuroscience, biotechnology, policy, and investment to examine one of the most urgent questions in medicine today: how to preserve brain health across the lifespan and accelerate progress against

For the third summer in a row, Longevity Xplorer (LongX) is opening applications for the Xplore Program, a fully remote summer fellowship designed to help students and early-career professionals translate interest in longevity into practical experience. The program is structured to do two things well: (1)

BERKELEY, CA — The Vitalism Foundation announces Vitalist Bay 2026, the world’s largest longevity festival, returning to the Lighthaven Campus in Berkeley, California from May 14–17, 2026. Now in its second year, Vitalist Bay condenses the scope into four high-intensity days and six themes — Biotech,

The NUS Academy for Healthy Longevity invites you to the Geromedicine Conference, set to take place from February 26-27, 2026, at the National University of Singapore. This premier event will gather global experts in geroscience, researchers, clinicians and industry leaders to explore the translation of geroscience

San Diego, CA – March 11–12, 2026 – Longevity Global will host the inaugural Longevity Innovation Forum, a two-day gathering bringing together leading scientists, clinicians, biotech founders, investors, and longevity enthusiasts advancing the science and translation of healthy aging. Held in San Diego’s thriving biotech hub,

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ER-100. The IND clearance allows Life Bio

Roatán, Honduras — Rejuve.AI is activating the International Longevity Research Database (IRLDB) through its first real-world study cohort at the Longevity Biomarkers Competition and Summit, taking place February to March 2026 as part of the Infinite Games in Roatán, Honduras. The IRLDB is being activated through

The Longevity World Forum announces its move to Madrid, reinforcing its international positioning with a new location aligned with its growth and leadership objectives in the field of longevity science and healthy ageing. The Spanish capital beats the cities that were postulated as possible venues for

Longevity Investors announces the upcoming Longevity Investors Lunch 2026, an exclusive, application-only gathering designed specifically for investors seeking exposure to the most compelling opportunities emerging at the intersection of longevity science, technology, and capital. Held during the World Economic Forum in Davos, the event convenes a

Why do we age at all, and why do different species age at such dramatically different rates? After decades of longevity research, biologists still disagree on the most basic questions: What is aging? Is it possible to stop or reverse it? And what strategies stand a

Cambridge, MA, USA – November 18, 2025: Vincere Biosciences today announced the receipt of a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutics Pipeline Program, which supports the advancement of promising therapies through preclinical and clinical stages. The

Nov 7, 2025 – Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the launch of its innovative cardiometabolic disease portfolio of unique highly-differentiated molecules discovered using generative AI. Powered by Insilico’s proprietary end-to-end Pharma.AI platform, the portfolio covers